ライフサイエンスコーパス: sudden cardiac death

1 n 64 families (230 relatives, 80 unexplained sudden cardiac death).

2 (HCM) is an uncommon but important cause of sudden cardiac death.

3 ies have focused on identifying high-risk of sudden cardiac death.

4 olongation, which poses an increased risk of sudden cardiac death.

5 n HFpEF, which in turn predisposes to VA and sudden cardiac death.

6 turely from ventricular tachycardia (VT) and sudden cardiac death.

7 rdiac hypertrophy are major risk factors for sudden cardiac death.

8 n associated with delayed repolarization and sudden cardiac death.

9 rs are indicated for prevention of secondary sudden cardiac death.

10 of lesions lead to heart attack, stroke, or sudden cardiac death.

11 main goal of treatment is the prevention of sudden cardiac death.

12 She had no family history of sudden cardiac death.

13 S2), a heart rhythm disorder associated with sudden cardiac death.

14 ias, leading to ventricular fibrillation and sudden cardiac death.

15 riggered syncope, aborted cardiac arrest, or sudden cardiac death.

16 ricular tachycardia (VT) is a major cause of sudden cardiac death.

17 table cardioverter-defibrillator shocks, and sudden cardiac death.

18 act obstruction, and risk stratification for sudden cardiac death.

19 All-cause mortality and sudden cardiac death.

20 ricular arrhythmias and an increased risk of sudden cardiac death.

21 e been linked to ventricular arrhythmias and sudden cardiac death.

22 achycardia, aborted sudden cardiac death, or sudden cardiac death.

23 ical interventions with potential to prevent sudden cardiac death.

24 osis (CS) may manifest as arrhythmia or even sudden cardiac death.

25 -myocyte junction and are a leading cause of sudden cardiac death.

26 ading to impaired mechanical contraction and sudden cardiac death.

27 tor (ICD) in the treatment and prevention of sudden cardiac death.

28 ardial repolarization and are susceptible to sudden cardiac death.

29 roke, invasive cardiovascular procedures, or sudden cardiac death.

30 ication and treatment of patients at risk of sudden cardiac death.

31 h risk indicator for cardiac arrhythmias and sudden cardiac death.

32 den cardiac death as compared with explained sudden cardiac death.

33 lications of heart disease and can result in sudden cardiac death.

34 tricular tachycardia or long QT syndrome and sudden cardiac death.

35 eading cause of mortality on hemodialysis is sudden cardiac death.

36 h risk indicator for cardiac arrhythmias and sudden cardiac death.

37 is a risk factor for cardiac arrhythmias and sudden cardiac death.

38 lock, atrial or ventricular arrhythmias, and sudden cardiac death.

39 evation myocardial infarction and 6 (17%) as sudden cardiac death.

40 for a group known to have elevated rates of sudden cardiac death.

41 e to ischemia-associated QT prolongation and sudden cardiac death.

42 scar and hibernation can inform the risk of sudden cardiac death.

43 d by cardiac hypertrophy, heart failure, and sudden cardiac death.

44 and the mechanisms of arrhythmias leading to sudden cardiac death.

45 r ICD implantation for primary prevention of sudden cardiac death.

46 inherited cardiac disorders associated with sudden cardiac death.

47 ventricular arrhythmias, cardiac arrest, and sudden cardiac death.

48 to advance the science and clinical care of sudden cardiac death.

49 for studying arrhythmic disorders leading to sudden cardiac death.

50 interval (Tp-e) is an independent marker of sudden cardiac death.

51 nsive research, as it increases the risk for sudden cardiac death.

52 to model and study disorders associated with sudden cardiac death.

53 s associated with poor cardiac prognosis and sudden cardiac death.

54 such as epilepsy, schizophrenia, cancer, and sudden cardiac death.

55 ncreasing the risk of Torsade de pointes and sudden cardiac death.

56 ts with myocardial ischemia, arrhythmia, and sudden cardiac death.

57 adian pattern of ventricular tachyarrhythmia/sudden cardiac death.

58 contributing to ventricular arrhythmias and sudden cardiac death.

59 syndrome type 1, which can cause syncope and sudden cardiac death.

60 es the risk for ventricular fibrillation and sudden cardiac death.

61 ide range of symptoms and may even result in sudden cardiac death.

62 ay result in serious consequences, including sudden cardiac death.

63 pathogenesis of ventricular arrhythmias and sudden cardiac death.

64 tent >15% it is associated with high risk of sudden cardiac death.

65 opathy and a low-intermediate 5-year risk of sudden cardiac death.

66 eating heart failure and reduce the risk for sudden cardiac death.

67 function, life-threatening arrhythmias, and sudden cardiac death.

68 man (QTc, >480 ms) with a family history of sudden cardiac death.

69 entricular Arrhythmias and the Prevention of Sudden Cardiac Death.

70 ted fat increase the risk of arrhythmias and sudden cardiac death.

71 ventricular walls and is a leading cause of sudden cardiac death.

72 seases and is associated with a high risk of sudden cardiac death.

73 ral regurgitation, and it is associated with sudden cardiac death.

74 luding myocardial fibrofatty replacement and sudden cardiac death.

75 d with malignant ventricular arrhythmias and sudden cardiac death.

76 es de pointes, and aborted cardiac arrest or sudden cardiac death.

77 eart disease, cardiomyopathy, arrhythmia, or sudden cardiac death.

78 e myocardium, resulting in heart failure and sudden cardiac death.

79 int of significant ventricular arrhythmia or sudden cardiac death.

80 nisms leading to acute coronary syndrome and sudden cardiac death.

81 from cardiovascular causes, of which 15 were sudden cardiac deaths.

82 age had the highest incidence of unexplained sudden cardiac death (0.8 cases per 100,000 persons per

83 .89]), and not associated with arrhythmia or sudden cardiac death (0.95 [0.76-1.19]).

84 al]) of cardiac death (1.45 [1.24 to 1.69]), sudden cardiac death [1.70 (1.34 to 2.15)], first cardio

85 strongest predictor for all-cause death and sudden cardiac death (10.09%, 95% CI 4.72-20.42% and 16.

86 ost common cause of cardiovascular death was sudden cardiac death (20.1%); while myocardial infarctio

87 35 years of age had the highest incidence of sudden cardiac death (3.2 cases per 100,000 persons per

88 ventricular arrhythmias (82%); and frequent sudden cardiac death (40 cases in 21 of 28 families).

89 Unexplained sudden cardiac death (40% of cases) was the predominant

90 revealed highly prevalent family history of sudden cardiac death (51%) and cardiomyopathy (72%) amon

91 hronic heart failure (42%), pneumonia (10%), sudden-cardiac death (7%), cancer (6%), and hemorrhage (

92 cturally normal heart carries a low risk for sudden cardiac death; accordingly, there is typically no

93 potential was associated with higher risk of sudden cardiac death (adjusted hazard ratio, 1.18; 95% c

94 ad disease progression and one patient died (sudden cardiac death after 17 months of ibrutinib mainte

95 ilure (aHR: 1.95; 95% CI: 1.11 to 3.41), and sudden cardiac death (aHR: 3.75; 95% CI: 1.26 to 11.2) o

96 romycin increases risk of cardiovascular and sudden cardiac death, although the underlying mechanisms

97 However, the recognition of the risk for sudden cardiac death among basketball players is challen

98 hic, and autopsy information on all cases of sudden cardiac death among children and young adults 1 t

99 Sudden cardiac death among children and young adults is

100 ed the identification of a possible cause of sudden cardiac death among children and young adults.

101 ulation-based, clinical and genetic study of sudden cardiac death among children and young adults.

102 ew-user design to compare the 1-year risk of sudden cardiac death among hemodialysis patients initiat

103 in reducing risk of all-cause mortality and sudden cardiac death among patients with an EF </=35% at

104 muM) had a 4-fold higher risk of cardiac or sudden cardiac death and a 2-fold higher risk of any-cau

105 d cardiomyopathy (DCM) is a leading cause of sudden cardiac death and a major indicator for heart tra

106 ndividuals, can acutely increase the risk of sudden cardiac death and acute myocardial infarction in

107 The secondary outcomes were sudden cardiac death and cardiovascular death.

108 of myocardial fibrosis predicts both risk of sudden cardiac death and likelihood of LV functional rec

109 myectomy with long-term follow-up, (aborted) sudden cardiac death and mortality rates were found to b

110 Modes of death were divided into sudden cardiac death and nonsudden death and compared be

111 ons for prediction and prevention of SCA and sudden cardiac death and provides justification for a re

112 f creating parametric risk models to predict sudden cardiac death and pump failure in the DCM populat

113 on, which carries significant mortality from sudden cardiac death and pump failure.

114 ations: For this review, we analyzed data on sudden cardiac death and SCA available from population s

115 (AF) predispose to ventricular arrhythmias, sudden cardiac death and stroke.

116 ciated with a transient elevation in risk of sudden cardiac death and that appropriate training subst

117 The primary focus has been sudden cardiac death and the utility of screening with o

118 nt of our analyses, whereas the composite of sudden cardiac death and ventricular tachycardia requiri

119 fatal and nonfatal myocardial infarction and sudden cardiac death), and harms.

120 sease severity expression, high-incidence of sudden cardiac death, and absence of skeletal myopathy o

121 all-cause mortality, heart transplantation, sudden cardiac death, and appropriate implantable cardio

122 and ICD implantation on all-cause mortality, sudden cardiac death, and cardiovascular death.

123 pically required due to an elevated risk for sudden cardiac death, and catheter ablation can be used

124 ar tachycardia, syncope, a family history of sudden cardiac death, and severe cardiac hypertrophy are

125 ications known as the stroke-heart syndrome, sudden cardiac death, and Takotsubo syndrome, among othe

126 years, 22 patients had hard cardiac events (sudden cardiac death, appropriate implantable cardiovert

127 ars (2 to 8 years), the combined endpoint of sudden cardiac death, appropriate implantable cardiovert

128 ter defibrillators for primary prevention of sudden cardiac death are less likely to experience susta

129 nce of sustained ventricular arrhythmias and sudden cardiac death are lower in women than in men.

130 (AF), sustained ventricular arrhythmias, and sudden cardiac death are recognized.

131 ations, including pulmonary hypertension and sudden cardiac death, are significantly higher for peopl

132 s worse compared with other etiologies, with sudden cardiac death as an important mode of death.

133 re independently associated with unexplained sudden cardiac death as compared with explained sudden c

134 There has been a decrease in aborted sudden cardiac death as the first manifestation of the d

135 peripheral artery disease, heart failure and sudden cardiac death, as well as how to select available

136 based on an estimate of a patient's risk of sudden cardiac death, as well as their preferences and v

137 These sudden cardiac deaths associated with Lyme carditis occu

138 overter-defibrillator firings and arrhythmic sudden cardiac death) at 5 years of follow-up.

139 icologic and histologic studies (unexplained sudden cardiac death), at least 59 cardiac genes were an

140 ecutive families who experienced unexplained sudden cardiac death before 45 years of age were include

141 cardiac syncope, aborted cardiac arrest, and sudden cardiac death, but a 38.8-fold (95% CI, 5.6-269.1

142 as emerged as a novel tool for prevention of sudden cardiac death, but clinical performance data for

143 Ds) improve survival in patients at risk for sudden cardiac death, but complications remain an import

144 recommended at autopsy in suspected cases of sudden cardiac death, but data on the role of nonselecti

145 onventionally been used as a risk marker for sudden cardiac death, but has performed poorly in trials

146 cardiomyopathy (ARVC) is a leading cause of sudden cardiac death, but its progression over time and

147 ic heart failure are at an increased risk of sudden cardiac death, but more discriminating tools are

148 hERG) ion channel, have been associated with sudden cardiac death, but only a subset of these variant

149 Catastrophic arrhythmias and sudden cardiac death can occur with even a small imbalan

150 nes can pre-dispose to 4 important causes of sudden cardiac death: cardiomyopathy, coronary artery di

151 in a case-control cohort of 600 adult-onset sudden cardiac death cases and 600 matched controls from

152 Among the 1,200 sudden cardiac death cases and controls, the authors ide

153 ine receptor-2 (RyR2) gene in both SUDEP and sudden cardiac death cases linked to catecholaminergic p

154 he prevalence of rare pathogenic variants in sudden cardiac death cases versus controls, and the prev

155 Although rare, sudden cardiac death caused by Lyme disease might be an

156 Hypertension is a risk factor for sudden cardiac death caused by ventricular tachycardia a

157 15 individuals, all of whom had experienced sudden cardiac death-corresponding to a pathogenic varia

158 is review article, part of the Compendium on Sudden Cardiac Death, discusses the major issues related

159 Overall, 14 of 50 patients suffered a sudden cardiac death during follow-up, with a cumulative

160 tients, both in the placebo group, died from sudden cardiac death during follow-up.

161 ular ejection fraction for the prediction of sudden cardiac death events.

162 Sudden cardiac death (fatal or aborted) was the primary

163 For sudden cardiac death, FHSD, nsVT, and obstruction showed

164 ound that the mice developed CCD, leading to sudden cardiac death from complete heart block, but no l

165 Risk stratification in the context of sudden cardiac death has been acknowledged as one of the

166 Although sudden cardiac death has been broadly studied, little is

167 ; 95% confidence interval, 1.31 to 6.82) and sudden cardiac death (hazard ratio, 4.52; 95% confidence

168 Some patients are at increased risk of sudden cardiac death, heart failure, and atrial fibrilla

169 tes conferred a higher risk of non-CV death, sudden cardiac death, hospitalization, CV hospitalizatio

170 id not receive defibrillators was related to sudden cardiac death in 8.0% among those with ICM but in

171 ong QT syndrome (LQTS) is a leading cause of sudden cardiac death in early life and has been implicat

172 32% versus 17%, P=0.020), and higher rate of sudden cardiac death in first degree relatives<age 30 (4

173 relatives without children and families with sudden cardiac death in first-degree relatives <40 years

174 crease the susceptibility to arrhythmias and sudden cardiac death in HD patients.

175 Utilising the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registr

176 tive analysis examined data collected in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT),

177 The SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) randomized

178 eceiving ICDs as part of the SCD-HeFT trial (Sudden Cardiac Death in Heart Failure Trial).

179 ormance was assessed in the SCD-HeFT cohort (Sudden Cardiac Death in Heart Failure Trial; n=2521).

180 rillator (ICD) use for primary prevention of sudden cardiac death in heart failure with reduced eject

181 s generally and patients at risk for SCA and sudden cardiac death in particular is limited by the div

182 dioverter-defibrillators are used to prevent sudden cardiac death in patients with cardiac sarcoidosi

183 tor (ICD) is the standard therapy to prevent sudden cardiac death in patients with coronary artery di

184 prolonged QT intervals, cardiomyopathy, and sudden cardiac death in several pedigrees.

185 bility is a well-established risk factor for sudden cardiac death in survivors of acute myocardial in

186 sociation between these 'maladaptations' and sudden cardiac death in the general population raises th

187 Current risk stratification strategies for sudden cardiac death in the heart failure patient are no

188 hly increased and so far unexplained risk of sudden cardiac death in the hemodialysis patient populat

189 A significant proportion of sudden cardiac death in the young (<=35 years) events ma

190 review will outline the underlying causes of sudden cardiac death in the young and outline our univer

191 diomyopathy (ARVC) is a significant cause of sudden cardiac death in the young.

192 fied in 31 of 113 cases (27%) of unexplained sudden cardiac death in which genetic testing was perfor

193 It is also the most common cause of sudden cardiac death in young adults and a major cause o

194 y artery (CA) is the second leading cause of sudden cardiac death in young athletes.

195 e diseases are often the underlying cause of sudden cardiac death in young individuals and result fro

196 rhythmic syncope, aborted cardiac arrest, or sudden cardiac death) in LQT3 patients.

197 g arrhythmic events (LAE) (cardiac arrest or sudden cardiac death) in SQTS patients.

198 associates with cardiovascular mortality and sudden cardiac death independent of traditional risk fac

199 Sudden cardiac death is a common cause of death in patie

200 Sudden cardiac death is a complication of a number of ca

201 Sudden cardiac death is a major contributor to mortality

202 Sudden cardiac death is common in humans with restrictiv

203 Sudden cardiac death is defined as a death occurring usu

204 The incidence of sudden cardiac death is higher in US basketball players

205 Sudden cardiac death is responsible for half of all deat

206 In individuals aged <35 years, unexplained sudden cardiac death is the most common presentation.

207 Long QT syndrome has been associated with sudden cardiac death likely caused by early afterdepolar

208 Sudden cardiac death occurred in 24 patients (4.3%) in t

209 omnolence and gastrointestinal symptoms; one sudden cardiac death occurred in the SEP-363856 group.

210 13% of the families in which an unexplained sudden cardiac death occurred.

211 Sudden cardiac death occurs in ~220,000 U.S. adults annu

212 l, 0.92-0.98; P=0.004) and family history of sudden cardiac death (odds ratio, 3.5; 95% confidence in

213 LTVTA was defined as (1) sudden cardiac death or (2) implantable cardioverter def

214 lant and a secondary arrhythmic end point of sudden cardiac death or appropriate implantable cardiove

215 admission for heart failure, 8% experienced sudden cardiac death or equivalent, 4% required heart tr

216 onal class, and 6 patients (27%) experienced sudden cardiac death or equivalent.

217 athy (AC) is a hereditary disease leading to sudden cardiac death or heart failure.

218 MYL4 expression did not associate with sudden cardiac death or other cardiomyopathies.

219 Patients with Brugada syndrome and aborted sudden cardiac death or syncope have higher risks for ve

220 t failure (HR, 1.48; 95% CI, 1.43-1.53), and sudden cardiac death or ventricular arrhythmia (HR, 1.65

221 rdial infarction, heart failure, stroke, and sudden cardiac death or ventricular arrhythmia.

222 The composite incidence of sudden cardiac death or ventricular tachycardia was 41%

223 for major arrhythmic events (sustained VAs, sudden cardiac death, or appropriate ICD therapy) in asy

224 d with a history of ventricular arrhythmias, sudden cardiac death, or implantable cardioverter-defibr

225 , sustained ventricular tachycardia, aborted sudden cardiac death, or sudden cardiac death.

226 inheritance of the condition and the risk of sudden cardiac death, other family members are tested fo

227 However, HCM is also an important cause of sudden cardiac death, particularly in adolescents and yo

228 rited heart muscle disorder, predisposing to sudden cardiac death, particularly in young patients and

229 Gene delivery of Ang-(1-9) reduced sudden cardiac death post-MI.

230 vices in heart failure with primary focus on sudden cardiac death prevention and cardiac resynchroniz

231 efibrillators (ICDs) are a standard means of sudden cardiac death prevention.

232 efibrillator (ICD) is safe and effective for sudden cardiac death prevention.

233 ibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patien

234 ars, whereas for patients >70 years old, the sudden cardiac death rate was 1.6 (95% CI, 0.8-3.2) and

235 For patients </=70 years old, the sudden cardiac death rate was 1.8 (95% CI, 1.3-2.5) and

236 , 0.66; 95% confidence interval, 0.50-0.87), sudden cardiac death (relative hazard, 0.57; 95% confide

237 ommon cyanotic congenital heart disease, and sudden cardiac death represents an important mode of dea

238 as a base case, the complex epidemiology of sudden cardiac death risk and the substantial new fundin

239 Using sudden cardiac death risk as a base case, the complex ep

240 l decision is whether a particular patient's sudden cardiac death risk is sufficient to justify place

241 hed and emerging factors to be considered in sudden cardiac death risk stratification.

242 The model is developed for the case of sudden cardiac death risk, but the concept is applicable

243 In the current therapeutic era, the risk for sudden cardiac death (SCD) after non-ST-segment elevatio

244 ic heart failure (HF) have increased risk of sudden cardiac death (SCD) and death from progressive pu

245 ite recent progress in profiling of risk for sudden cardiac death (SCD) and prevention and interventi

246 Although cardio-vascular incidents and sudden cardiac death (SCD) are among the leading causes

247 Sudden cardiac arrest and sudden cardiac death (SCD) are terms often used intercha

248 Most sudden cardiac death (SCD) events occur in the general p

249 Sudden cardiac death (SCD) from arrhythmias is a leading

250 Although the occurrence of sudden cardiac death (SCD) in a young person is a rare e

251 Accurate knowledge of causes of sudden cardiac death (SCD) in athletes and its precipita

252 The incidence and cause of sudden cardiac death (SCD) in athletes is debated with h

253 lectrocardiographic parameters as markers of sudden cardiac death (SCD) in BrS.

254 ophic cardiomyopathy is the leading cause of sudden cardiac death (SCD) in children and young adults.

255 s have a higher incidence of out-of-hospital sudden cardiac death (SCD) in comparison with whites.

256 ime physical activity (LTPA) and the risk of sudden cardiac death (SCD) in coronary artery disease pa

257 The risk of sudden cardiac death (SCD) in patients with heart failur

258 Sudden cardiac death (SCD) in the young is devastating.

259 cardiomyopathy for the primary prevention of sudden cardiac death (SCD) in those with a left ventricu

260 pathy (HCM) is considered a leading cause of sudden cardiac death (SCD) in younger people.

261 Sudden cardiac death (SCD) is a devastating event afflic

262 Sudden cardiac death (SCD) is a major cause of mortality

263 The risk of sudden cardiac death (SCD) is high early after myocardia

264 Sudden cardiac death (SCD) is the leading cause of morta

265 Sudden cardiac death (SCD) is the most devastating manif

266 Arrhythmic sudden cardiac death (SCD) may be caused by ventricular

267 Conventional definitions of sudden cardiac death (SCD) presume cardiac cause.

268 tachyarrhythmias with device-based therapy, sudden cardiac death (SCD) remains an enormous public he

269 assessed the echocardiographic predictors of sudden cardiac death (SCD) within 2 population-based coh

270 by ventricular arrhythmias, that can lead to sudden cardiac death (SCD) within minutes.

271 l heart disease carries an elevated risk for sudden cardiac death (SCD), and implantable cardioverter

272 dialysis are reported to be at high risk of sudden cardiac death (SCD), and to date, no therapy has

273 rofatty replacement and an increased risk of sudden cardiac death (SCD).

274 gation of the QT interval is associated with sudden cardiac death (SCD).

275 ament protein leads to an increased risk for sudden cardiac death (SCD).

276 may be associated with an increased risk of sudden cardiac death (SCD).

277 ythmia syndromes are at an increased risk of sudden cardiac death (SCD).

278 pertrophic cardiomyopathy is associated with sudden cardiac death (SCD).

279 has assessed whether it is a risk factor for sudden cardiac death (SCD).

280 dentified in approximately 80% of victims of sudden cardiac death (SCD).

281 ntricular arrhythmia is the leading cause of sudden cardiac death (SCD).

282 ciated with ventricular arrhythmias (VA) and sudden cardiac death (SCD).

283 e of arrhythmia, which is a leading cause of sudden cardiac death (SCD).

284 erogeneous phenotype, with increased risk of sudden cardiac death (SCD).

285 The majority of sudden cardiac deaths (SCDs) occur in low-risk populatio

286 atic individuals account for the majority of sudden cardiac deaths (SCDs).

287 Ventricular tachyarrhythmias and sudden cardiac death show a circadian pattern of occurre

288 st device implantation (DHF/HTx/VAD); and 3) sudden cardiac death/sustained ventricular tachycardia/v

289 ally important subset of adults experiencing sudden cardiac death; these variants are present in ~1%

290 leads to the pandemics of heart failure and sudden cardiac death, thus calling for a reappraisal of

291 Patients with an increased risk of sudden cardiac death undergo cardioverter-defibrillator

292 hy and a low- or intermediate 5-year risk of sudden cardiac death underwent cardiac magnetic resonanc

293 hanical circulatory support/transplantation, sudden cardiac death, vascular outcomes in coarctation o

294 Sudden cardiac death was not observed in young pigs; how

295 rillators (ICDs) for secondary prevention of sudden cardiac death were conducted nearly 2 decades ago

296 The most common explained causes of sudden cardiac death were coronary artery disease (24% o

297 A total of 490 cases of sudden cardiac death were identified.

298 defined as stroke, myocardial infarction, or sudden cardiac death, were assessed prospectively over a

299 s to very low values before they suffer from sudden cardiac death with an unexplained high incidence.

300 After sudden cardiac death with negative autopsy, clinical scr